45 results about "Allogeneic graft" patented technology

Disclosed herein are methods for sequencing, comprising, providing a sample, wherein said sample comprises a plurality of nucleic acid (NA) molecules, isolating said plurality of NA molecules from said sample, amplifying said plurality of NA molecules, subjecting said plurality of NA molecules to one or more amplification reactions to generate a plurality of cDNA molecules, and sequencing said plurality of cDNA molecules or derivatives thereof. Also disclosed herein are systems, comprising, a processor, and a non-transitory computer readable storage medium encoded with a computer program that causes said processor to providing a sample, wherein said sample comprises a plurality of NA molecules, isolating said plurality of NA molecules from said sample, amplifying said plurality of NA molecules, subjecting said plurality of nucleic acid molecules to one or more amplification reactions to generate a plurality of cDNA molecules, and sequencing said plurality of cDNA molecules or derivatives thereof.

The art does not provide systematic and reproducible methods to personalize dosing of multiple immunosuppressive medications after transplantation. This invention provides a method to systematize multi-drug immuno suppression management in tissue and organ transplantation using an artificial intelligence-based complex systems approach. In embodiments of this invention, immunosuppression drug dose, blood drug concentrations, donor-derived fraction of cell free DNA (dd-cfDNA %), and aspartate aminotransferase are used to indicate allograft status or a proxy for allograft status, to generate a phenotypic response surface to produce individual treatment modalities and dosages using empirically determined unique coefficients. This surface is used to calculate appropriate immunosuppression drug doses associated with the desired outcome for that patient. Embodiments of this disclosure are directed to identifying optimized combinations of inputs for the complex system of the immunosuppressed transplant patient in order to avoid transplant rejection while avoiding unnecessary toxicity and maintaining a robust enough immune response to fight infection.

Embodiments of systems and methods for fixing soft tissue are disclosed herein. In some embodiments, soft tissue may be fixed to an attachment surface (such as bone, other soft tissue, other implants, or allograft or xenograft materials) by providing a helical suture in the soft tissue, wherein the soft tissue has a longitudinal axis along which the soft tissue undergoes tension under normal physiological conditions, and wherein a longitudinal axis of the helical suture in the soft tissue is oriented parallel to the longitudinal axis of the soft tissue; and securing the helical suture to an anchor secured to the attachment surface.

Organ transplantation is currently recognized as the treatment of choice for patients with end-stage renal disease (ESRD). To date, no risk-stratification system exists that adequately predicts transplant patients' individual risk of allograft loss. Described herein the development and validation of an integrative risk prediction score to predict kidney allograft survival of individual patients. A methodology of predicting whether a kidney transplant recipient is at risk of having allograft loss is accomplished by implementing the iBox risk prediction score. The methodology can be achieved using a computer-readable storage medium with program instructions which, when executed by a data-processing unit, cause execution of at least the step of implementing an algorithm of said method of predicting whether a kidney transplant recipient is at risk of having allograft loss.

Improved allografts having controlled and consistent properties and useful for soft tissue repair, including breast reconstruction, and other surgical procedures, are disclosed. In one embodiment, an improved acellular dermal matrix (ADM) is produced from a skin sample, where the ADM consists essentially of a single dermal tissue type (e.g., papillary or reticular) and comprises a collagen matrix having substantially uniform density and porosity. In another embodiment, two ADMs are produced from the same dermal tissue type (e.g., papillary or reticular) of the same skin sample, each of which consists essentially of reticular dermis, and comprises a collagen matrix having substantially uniform density and porosity. All such improved ADMs are suitable for use in breast reconstruction and other tissue repair and modification surgery procedures.

A device and system for inserting and impacting bone dowel allografts or bone chips into a bone tunnel. The surgical impacting system includes a surgical tamp having a proximal end and a distal end with an elongated shaft extending therebetween. The surgical tamp has an inner channel extending therethrough from the proximal end to the distal end. The distal end of the surgical tamp can have a distal tip. The surgical tamp may have a handle at the proximal end or a proximal tip at the proximal end. The surgical tamp may also have one or more slots extending through the exterior surface of the elongated shaft and into the inner channel. The surgical tamp can be configured for insertion into a delivery tube. The delivery tube serves the purpose of containing a bone dowel or bone chips therein for smooth insertion into the joint.

Provided herein are a method of processing human birth tissue to create a variety of tissue forms that maintain high levels of beneficial compounds and increase tissue availability. Also provided are products made from the processed tissue forms, and application of these products in soft tissue repair and the treatment of wounds.

The invention relates to allograft tolerance without systemic immune containment. There is provided a cell genetically modified to comprise at least one mechanism for providing localized immune containment at a transplantation site when transplanted into an allogeneic host; and methods for making and using the cells. The cell comprises a set of transgenes, each transgene encoding a gene product of cytoplasm, membrane binding or topical action, and having one or more of the following functions: mitigating antigen presenting cell activation and function; mitigating leukocyte activity or cytolytic function of the aggressive graft; the cytolytic function and phagocytosis of macrophages of allograft cells are reduced; inducing apoptosis in the graft-attacking leukocytes; reducing local inflammatory proteins; and protecting from leukocyte mediated apoptosis.

Provided herein are a method of processing human birth tissue to create a variety of tissue forms that maintain high levels of beneficial compounds and increase tissue availability. Also provided are products made from the processed tissue forms, and application of these products in soft tissue repair and the treatment of wounds.

A method of preparing sterile human placental allografts by providing a human placental tissue from a donor within 24 hours to 72 hours post-childbirth; removing any visible blood, blood clots, and / or blood components from the human placental tissue without scraping or scrubbing the human placental tissue to preserve structural integrity of the human placental tissue; washing the human placental tissue in an isotonic solution while maintaining the structural integrity of the human placental tissue; dehydrating the human placental tissue thereby forming the dehydrated human placental tissue; resizing the dehydrated human placental tissue into dehydrated human placental tissue portions having predetermined sizes; and sterilizing the dehydrated human placental tissue portions of step (e) thereby forming the sterile human placental allograft. Also disclosed is a sterile human placental allograft produced by the method.

The present application relates to a bifunctional therapeutic substance for treating cancer, comprising a targeting component that targets a tumor-associated antigen and an enzyme that, when delivered to a tumor by the targeting component, converts the tumor phenotype into the phenotype of a mismatched allograft or xenograft. The enzyme is connected to the targeting component. Also disclosed is a method for treating cancer, comprising the step of administering the bifunctional therapeutic substance.

There is disclosed an acellular dermal matrix (ADM) graft stored as a packaged ADM graft pocket product prepared by a process that includes providing a portion of ADM tissue having a thickness between 1 mm and 2 mm. The process includes scoring the portion of the ADM tissue into a pre-defined shape to form the domed shape ADM graft. The process includes verifying the thickness of the domed shape ADM graft; shaping the domed shape ADM graft to form an ADM graft pocket configured to receive a breast implant. The process includes packaging the ADM graft pocket to form a packaged ADM graft pocket. The process includes irradiating the packaged ADM graft pocket to a sterility assurance level of a desired level to form the packaged ADM graft pocket product. Other embodiments are also disclosed.

Pre-existing alloreactive memory T cells are a major barrier to the induction of allograft tolerance in organ transplant recipients. The use of Eomesodermin (Eomes) expression in memory T cells to determine the risk of allograft rejection in a subject is described. Also described is the use of Eomes expression in memory T cells of transplant recipients to modify immunosuppressive therapy.

The present invention relates to the use of bone graft particles in the preparation of a porous bone graft material comprising an acid-containing self-setting adhesive composition. The bone graft particles have a porous core, the outer surface of which is at least partially covered by an outer layer. The core comprises a core material selected from the group consisting of a heterograft, a bone xenograft, and a bone allograft, or mixtures thereof. And the outer particle layer comprises carbonate.

The disclosure herein relates to isolated and purified mammalian fetal allografts and kits and compositions containing these. Also disclosed are methods of preparing isolated and purified mammalian fetal allografts; methods of contacting a wound of a subject with these, and methods of treating a disease or condition with these.

An allograft preparation station includes a frame and a cutting guide. The frame includes a pair of outer members and a pair of inner members receivable in respective outer members of the pair of outer members. The pair of inner members, when coupled to the frame, may be adjusted to grip a bone from opposing sides of the bone. The cutting guide may be separately secured to the bone to guide cutting of the bone in order to extract an allograft from the bone.

Provided herein are formulations for treating bone graft materials prior to implantation. Treating the bone graft materials with the formulations disclosed herein can restore the physiological and biochemical characteristics of bone. The bone graft can be a bone allograft. Also provided herein are methods for preparing the formulations and methods for preparing a bone graft for transplantation.

The invention features compositions and methods for treating transplant recipients (e.g., chronic allograft rejection) using a senolytic agent and an angiotensin II receptor antagonist or using a senolytic agent and senomorphic agent. The methods and compositions are useful in a variety of transplant settings including, without limitation, solid organ transplants including kidney, lung, heart, liver, intestine, or pancreas transplantation procedures and cellular transplants including but not limited to bone marrow transplants.

Disclosed herein are methods of treating a disease selected from the group consisting of graft versus host disease (GVHD), systemic sclerosis (scleroderma), chronic lung allograft dysfunction (CLAD), restrictive allograft syndrome (RAS), and obliterated bronchitis syndrome (BOS), using a combination of a BTK inhibitor, such as rezobrutinib, and besudil.

Systems and methods for bone reconstruction. In some implementations the systems and methods may be used to remove and replace a bone portion with an implant, which may be an allograft, biomaterial, metal implant, or any other type of implant. The systems and methods may be used to make accurate cuts in bone to remove a diseased bone portion and then reproduce the cuts in a donor material to recreate the precise geometry of the removed portion. Additionally or alternatively, the system can check the accuracy of reconstruction when a segment of bone is replaced.

The present invention provides bone grafts, such as allografts, and methods of releasing growth factors from tissues with native living cells, such as bone marrow, bone matrix, adventitia and / or inventitia. Also provided are compositions comprising growth factors and uses of the compositions to improve osteoinductivity of implants, such as bone grafts.

Chronic Lung Allograft Dysfunction (CLAD) is characterized by a progressive and irreversible decline in lung function affecting half of lung transplant recipients within five years and is the major cause of death contributing to a low median post-transplant survival. Disclosed herein is an optimized airway inflammation gene set (AI2) and AI2 score, as well as RSI, RS2, and RS3 subscores, for use in methods of treating or preventing CLAD, methods of treating or preventing graft failure, methods of treating or preventing transplant rejection, methods of treating or preventing small airway fibrosis, methods of treating or preventing antibody mediated rejection (AMR) and methods of reducing mortality associated with graft failure. Also disclosed are methods of detecting or diagnosing CLAD and methods of predicting transplant rejection.

Chronic Lung Allograft Dysfunction (CLAD) is characterized by a progressive and irreversible decline in lung function affecting half of lung transplant recipients within five years and is the major cause of death contributing to a low median post-transplant survival. Disclosed herein is an optimized airway inflammation gene set (AI2) and AI2 score, as well as RS1, RS2, and RS3 subscores, for use in methods of treating or preventing CLAD, methods of treating or preventing graft failure, methods of treating or preventing transplant rejection, methods of treating or preventing small airway fibrosis, methods of treating or preventing antibody mediated rejection (AMR) and methods of reducing mortality associated with graft failure. Also disclosed are methods of method of detecting or diagnosing CLAD and methods of predicting transplant rejection.

The present disclosure pertains to a method for treating Type 1 diabetes mellitus by using tolerogenic dendritic cells (tDCs) as an adjunct to stem cell-derived β-cell (SCislet) replacement therapy. The tDCs are genetically modified to induce immunotolerance and are administered in conjunction with SCislet autografts or allografts to enhance their survival and function, providing a potential cure or disease-modifying treatment for T1DM.

Provided herein are bioresorbable, bioregenerative composite materials and compositions to regenerate tissues or organs to repair tissue or organ defects and constructs printed from the same as 3D structures shaped and sized to fill a tissue or organ defect. The composite materials are bioresorbable polymers, for example, polycaprolactone, and a bioresorbable graft material, for example, demineralized bone matrix. Also provided are methods for making the composite materials and compositions and methods for regenerating tissues or organs and repairing a tissue or organ defect using the constructs.

Disclosed herein includes a method for treating antibody-mediated kidney allograft rejection, comprising treating a subject determined to suffer from antibody-mediated kidney allograft rejection more than 6 months after transplantation by administering an anti-CD38 antibody or antigen-binding fragment thereof (e.g., daratumumab, felzartamab, or isatuximab) to the subject; extracting cell-free DNA from a blood, plasma, serum or urine sample collected from the subject after conclusion of the treatment; quantifying an amount of donor-derived cell-free DNA, a percentage of donor-derived cell-free DNA out of total cell-free DNA, or both, in the extracted DNA; and retreating the subject with an anti-CD38 antibody or antigen-binding fragment thereof if the amount of donor-derived cell-free DNA, the percentage of donor-derived cell-free DNA out of total cell-free DNA, or both, exceed one or more threshold values.

The present invention relates to compounds of formula (1) or (2), wherein R 1 and R 3 is a purine or a purine analog, and R 2 and R 4 is a small functional group. The present invention also relates to intermediates for the synthesis of compounds of formula 1 or 2. Compounds of formula 1 or 2 are Janus kinase inhibitors and are therefore useful for the treatment of diseases, in particular autoimmune diseases, cancer, Alzheimer's disease or for the prevention of rejection of allografts or xenografts.

Improved allografts having controlled and consistent properties and useful for soft tissue repair, including breast reconstruction, and other surgical procedures, are disclosed. In one embodiment, an improved acellular dermal matrix (ADM) is produced from a skin sample, where the ADM consists essentially of a single dermal tissue type (e.g., papillary or reticular) and comprises a collagen matrix having substantially uniform density and porosity. In another embodiment, two ADMs are produced from the same dermal tissue type (e.g., papillary or reticular) of the same skin sample, each of which consists essentially of reticular dermis, and comprises a collagen matrix having substantially uniform density and porosity. All such improved ADMs are suitable for use in breast reconstruction and other tissue repair and modification surgery procedures.